Overview
This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.
Description
PRIMARY OBJECTIVES:
I. To assess patient satisfaction with receiving IV immune checkpoint inhibitors, reflecting whether the patient thought that the experience was safe, convenient, comfortable and proceeded smoothly.
II. To assess patient preference for IV versus home SC ICI administration.
OUTLINE: This is an observational study.
Patients complete surveys on study.
Eligibility
Inclusion Criteria:
- \ Age ≥ 18 years.
- \ Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy)
- \ Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint.
- \ Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent.
Exclusion Criteria:
- \ Patients is unable to consent for themselves
- \ Patient has not yet completed the 1st cycle of ICI-based therapy
